In connection with the rights issue this summer, the biotechnology company Sprint Bioscience promised further investments in expanding the development portfolio. Now, about a week after completing the issue, the company has announced NIMA, a cancer project that targets a tumour’s microenvironment to affect the cancer’s ability to grow while at the same time making it easier for the immune system to attack it directly.
Read the full article at biostock.se:
This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.se